BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25173447)

  • 1. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor.
    Oya H; Kanda M; Sugimoto H; Shimizu D; Takami H; Hibino S; Hashimoto R; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Nomoto S; Fujiwara M; Kodera Y
    J Gastroenterol; 2015 May; 50(5):590-600. PubMed ID: 25173447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
    Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
    Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.
    Ezaka K; Kanda M; Sugimoto H; Shimizu D; Oya H; Nomoto S; Sueoka S; Tanaka Y; Takami H; Hashimoto R; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1499-507. PubMed ID: 26122373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer.
    Kanda M; Nomoto S; Oya H; Shimizu D; Takami H; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    J Exp Clin Cancer Res; 2014 Aug; 33(1):66. PubMed ID: 25096402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma.
    Tanaka Y; Kanda M; Sugimoto H; Shimizu D; Sueoka S; Takami H; Ezaka K; Hashimoto R; Okamura Y; Iwata N; Tanaka C; Yamada S; Fujii T; Nakayama G; Koike M; Nomoto S; Fujiwara M; Kodera Y
    Int J Oncol; 2015; 46(6):2546-54. PubMed ID: 25892360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation.
    Umetsu S; Mizukami H; Saito T; Uchida C; Igawa A; Kudo K; Itabashi C; Osonoi S; Danyang G; Sasaki T; Yagihashi S; Hakamada K
    Sci Rep; 2020 Jan; 10(1):1156. PubMed ID: 31980687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
    Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
    Liu L; Yang X; Li NF; Lin L; Luo H
    Cell Cycle; 2019 Nov; 18(21):2939-2953. PubMed ID: 31522588
    [No Abstract]   [Full Text] [Related]  

  • 9. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.
    Zhang C; Ge S; Wang J; Jing X; Li H; Mei S; Zhang J; Liang K; Xu H; Zhang X; Zhang C
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1869-1877. PubMed ID: 31038805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma.
    Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Hishida M; Suenaga M; Yamada S; Inokawa Y; Nishikawa Y; Asai M; Fujii T; Sugimoto H; Kodera Y
    Int J Oncol; 2014 Jan; 44(1):44-52. PubMed ID: 24189587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma.
    Umeda S; Kanda M; Sugimoto H; Tanaka H; Hayashi M; Yamada S; Fujii T; Takami H; Niwa Y; Iwata N; Tanaka C; Kobayashi D; Fujiwara M; Kodera Y
    BMC Cancer; 2017 Sep; 17(1):610. PubMed ID: 28863781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.
    Zhu J; Huang S; Wu G; Huang C; Li X; Chen Z; Zhao L; Zhao Y
    Dig Dis Sci; 2015 Oct; 60(10):3019-31. PubMed ID: 26048020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma.
    Kanda M; Sugimoto H; Nomoto S; Oya H; Shimizu D; Takami H; Hashimoto R; Sonohara F; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Int J Oncol; 2014 Nov; 45(5):2005-12. PubMed ID: 25189544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The suppressive role and aberrent promoter methylation of BTG3 in the progression of hepatocellular carcinoma.
    Lv Z; Zou H; Peng K; Wang J; Ding Y; Li Y; Ren X; Wang F; Chang R; Liang L; Ding Y
    PLoS One; 2013; 8(10):e77473. PubMed ID: 24147003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
    Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
    BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.
    Wu D; Yang X; Peng H; Guo D; Zhao W; Zhao C; Zhou X
    Carcinogenesis; 2017 Sep; 38(9):910-919. PubMed ID: 28911005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.
    Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW
    World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma.
    Zhang T; Guan G; Chen T; Jin J; Zhang L; Yao M; Qi X; Zou J; Chen J; Lu F; Chen X
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e352-e358. PubMed ID: 29749051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.